Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-25 @ 1:41 AM
Ignite Modification Date:
2025-12-25 @ 1:41 AM
NCT ID:
NCT00428194
Eligibility Criteria:
Inclusion Criteria:
* Diagnosis of squamous cell carcinoma of the cervix
* Stage IB-IVA disease
* Scheduled to undergo standard radiotherapy and receive weekly cisplatin
* ECOG performance status 0-2
* Not pregnant
* Negative pregnancy test
* Fertile patients must use effective contraception during and for ≥ 1 week after completion of study treatment
* Must be able to take oral medication
Exclusion Criteria:
* Malabsorption syndrome
* Serious underlying medical condition that would impair the ability of patient to receive treatment
* Known hypersensitivity to erlotinib hydrochloride
* Psychological, familial, sociological, or geographical conditions that would preclude study compliance
* Less than 21 days since prior nonapproved or investigational drugs
* Prior chemotherapy
* Prior radiotherapy
* Prior anti-epidermal growth factor receptor treatment
* Prior gastrointestinal surgery that limits absorption (i.e., requiring total parenteral nutrition)
* Concurrent use of any of the following agents and therapies:
* Other antineoplastic or antitumor agents
* Other chemotherapy
* Other investigational agents
* Radiotherapy
* Immunotherapy
* Anticancer hormonal therapy
Healthy Volunteers:
False
Sex:
FEMALE
Minimum Age:
18 Years
Study:
NCT00428194
Study Brief:
Protocol Section:
NCT00428194